Search

everythinglearnresearchcommunity

for

Search:↓

Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.

Combining ciclosporin and simvastatin can cause severe kidney damage.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

Tacrolimus is a better option than cyclosporine due to fewer side effects.

Topical tacrolimus is safe and effective for skin conditions, but oral tacrolimus has serious side effects.

Tacrolimus is an effective treatment for several skin conditions with fewer side effects than cyclosporine.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

The combined treatment effectively managed severe skin issues in Olmsted syndrome.

Tacrolimus ointment is effective for various skin conditions but needs more research for long-term effects.

A woman developed severe kidney injury from using simvastatin with ciclosporin, highlighting the need for careful monitoring when combining these drugs.

Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.

Tacrolimus is effective for various skin conditions with fewer side effects than cyclosporine.

Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.

The model and estimator can predict drug exposure in kidney transplant patients well.

Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.

Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.

Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Topical tacrolimus reduces certain growth factors in hair follicles.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

Sirolimus and propranolol may reduce abnormal cell growth and improve lymphatic malformations in children.

Rapamycin increased survival in mice with severe chronic graft-versus-host disease by expanding regulatory T cells.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.